



Supplementary Figure 3. S protein IgG subclasses responses in hypoxia or intubated patients with or without remdesivir (RDV) treatment. Plasma samples of non-intubated COVID-19 patients with RDV (n=21) or without RDV (n=17) treatment, and intubated COVID-19 patients with RDV (n=6) or without RDV (n=10) treatment were screened at 1:100 dilution against cells expressing the full-length SARS-CoV-2 spike protein, with healthy donors screened in parallel (n=22). (A) IgG1, (B) IgG2, (C) IgG3, and (D) IgG4 responses, (E) ratio of combined IgG2 and IgG4 to combined IgG1 and IgG3 response (IgG_{2/4}/IgG_{1/3}) in RDV-treated patients with or without intubation before and after treatment and also in non-RDV-treated patients at matched time point 1 and 2. Statistical analyses were performed with Wilcoxon matched-pairs signed rank test (**P*<0.05; ***P*<0.01; ****P*<0.001; *****P*<0.0001).